The goal of this clinical trial is to evaluate the efficacy and safety of Crisugabalin in adult participants with Parkinson's disease suffering from nociceptive pain. The main question it aims to answer is:
1. Does Crisugabalin significantly reduce pain intensity compared to placebo?
2. What is the safety and tolerability profile of Crisugabalin in patients with Parkinson's disease?
Researchers will compare participants receiving Crisugabalin to those receiving a matching placebo to see if the investigational drug leads to a greater reduction in pain scores and an improvement in quality of life without unacceptable side effects.
Participants will:
1. Be randomly assigned to receive either Crisugabalin capsules or a placebo.
2. Take the study medication orally twice daily for a specified treatment period.
3. Complete regular pain assessments using standardized scales (e.g., VAS or NRS).
4. Undergo physical examinations and laboratory tests to monitor safety.
5. Record any adverse events and changes in Parkinson's disease symptoms in a diary.